Surgalign Holdings EBITDA 2011-2026 | SRGA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Surgalign Holdings

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-76.3 M	-135 M	-72 M	19.3 M	21.1 M	28.3 M	12.8 M	43.8 M	26 M	-4.57 M	22.6 M	19.8 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
43.8 M	-135 M	-7.84 M

Quarterly EBITDA Surgalign Holdings

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-644 K	-	-6.26 M	-12.2 M	-8.36 M	-	-15.1 M	-12.1 M	-13.9 M	-	-20.6 M	-20.4 M	-25.6 M	-	-4.17 M	11.1 M	-3.14 M	-	15.7 M	-396 K	3.42 M	-	34.6 M	386 K	1.6 M	-	-3.57 M	-1.73 M	8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
34.6 M	-25.6 M	-3.34 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Medical devices industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Aethlon Medical AEMD	-9 M	$ 2.11	8.21 %	$ 3.29 M	USA
AdaptHealth Corp. AHCO	473 M	$ 10.42	-1.65 %	$ 1.41 B	USA
Allied Healthcare Products AHPI	-815 K	-	3.58 %	$ 2.21 M	USA
GenMark Diagnostics, Inc. GNMK	-3.98 M	-	-	$ 1.77 B	USA
Acutus Medical AFIB	-11.5 M	-	-26.83 %	$ 2.62 M	USA
Alphatec Holdings ATEC	-4.64 M	$ 12.6	2.61 %	$ 1.89 B	USA
Butterfly Network BFLY	-65.5 M	$ 3.91	2.62 %	$ 828 M	USA
Obalon Therapeutics, Inc. OBLN	-9.8 M	-	-5.86 %	$ 30.6 M	USA
Cognyte Software Ltd. CGNT	8.53 M	$ 8.38	-0.24 %	$ 602 M	Israel
Aziyo Biologics AZYO	-24.1 M	-	1.37 %	$ 20.5 M	USA
Avinger AVGR	-16.3 M	-	-20.74 %	$ 369 K	USA
BIOLASE BIOL	-15.1 M	-	-13.19 %	$ 166 K	USA
Boston Scientific Corporation BSX	4.98 B	$ 69.79	0.95 %	$ 103 B	USA
Conformis CFMS	-42.2 M	-	-	$ 16.4 M	USA
EDAP TMS S.A. EDAP	-18 M	$ 3.96	1.02 %	$ 148 M	France
CONMED Corporation CNMD	120 M	$ 37.41	0.35 %	$ 1.16 B	USA
Apollo Endosurgery APEN	-30.2 M	-	-	$ 475 M	USA
Cytosorbents Corporation CTSO	-15.2 M	$ 0.65	-8.13 %	$ 35.4 M	USA
Cutera CUTR	-148 M	-	-10.19 %	$ 1.99 M	USA
CryoLife, Inc. CRY	23.2 M	-	-4.14 %	$ 702 M	USA
Dynatronics Corporation DYNT	-1.97 M	-	14.99 %	$ 929 K	USA
ClearPoint Neuro CLPT	-18.8 M	$ 11.03	2.22 %	$ 298 M	USA
Establishment Labs Holdings ESTA	-32.8 M	$ 63.48	0.21 %	$ 1.88 B	Costa-rica
Axonics Modulation Technologies AXNX	-53.2 M	-	-	$ 3.31 B	USA
Soliton, Inc. SOLY	-14.1 M	-	-1.42 %	$ 435 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	88.4 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	-8.53 M	-	0.03 %	$ 1.58 B	Israel
Misonix, Inc. MSON	-15.9 M	-	-	$ 462 M	USA
Neovasc NVCN	-31.1 M	-	-	$ 111 M	Canada
FONAR Corporation FONR	9.84 M	$ 18.42	0.22 %	$ 121 M	USA
InMode Ltd. INMD	86.1 M	$ 13.43	-0.81 %	$ 868 M	Israel
GBS GBS	-9.67 M	-	-0.57 %	$ 7.12 M	USA
Intersect ENT, Inc. XENT	-64.8 M	-	-	$ 955 M	USA
Abbott Laboratories ABT	9.49 B	$ 109.95	1.8 %	$ 191 B	USA
Delcath Systems DCTH	898 K	$ 9.81	3.81 %	$ 351 M	USA
Bio-Rad Laboratories BIO	421 M	$ 261.24	-0.59 %	$ 7.37 B	USA
Helius Medical Technologies HSDT	-12.4 M	$ 2.19	3.79 %	$ 1.33 M	USA
Integra LifeSciences Holdings Corporation IART	70.8 M	$ 9.01	-2.49 %	$ 694 M	USA
AxoGen AXGN	-1.19 M	$ 32.84	1.55 %	$ 1.51 B	USA
Align Technology ALGN	753 M	$ 169.45	3.18 %	$ 12.7 B	USA
Bruker Corporation BRKR	437 M	$ 32.76	-2.93 %	$ 4.88 K	USA
IRIDEX Corporation IRIX	-8.91 M	$ 1.33	2.31 %	$ 21.5 M	USA
BioSig Technologies BSGM	-12.7 M	-	37.08 %	$ 85.7 M	USA
Apyx Medical Corporation APYX	-5.79 M	$ 3.67	1.1 %	$ 151 M	USA
OrthoPediatrics Corp. KIDS	-18.1 M	$ 17.11	-1.16 %	$ 401 M	USA
Integer Holdings Corporation ITGR	352 M	$ 84.12	1.34 %	$ 2.92 B	USA
Invacare Corporation IVC	-65 M	-	-	$ 24.7 M	USA
Second Sight Medical Products EYES	-24.3 M	-	-0.97 %	$ 54.4 M	USA